Finally, we assessed targeting FAP+ FRCs in other CD20-expressing B cell malignancies and confirmed that the addition of FAP-targeted immunostimulatory drugs could augment glofitamab-induced cytotoxicity in follicular lymphoma and Hodgkin lymphoma patient LNs when FAP was expressed by stromal cells (Supplemental Table 6 and Supplemental Figure 10, I–L). This evidence concerns the gene FAP and follicular lymphoma.